Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Adult-onset Still's Disease
NCT02204293Phase 2Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jun 2012
- Primary completion
- May 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in adult-onset Still's disease (AOSD), sponsored by Charité – Universitätsmedizin Berlin. Started Jun 2012; status: terminated.
02
Drugs
canakinumab
03
Conditions
adult-onset Still's disease (AOSD)
Beyond the preview
Go deeper on NCT02204293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204293.